Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.

Hanneke van der WijngaartLouisa R HoesJ Maxime van Berge HenegouwenDaphne L van der VeldenLaurien J ZeverijnPaul RoepmanErik D van WerkhovenWendy W J de LengAnne M L Jansen Niven Mehra Debbie G J RobbrechtMariette LabotsDerk Jan A de GrootAnn HoebenPaul HambergAndré B P van KuilenburgEmile E VoestHenk M W Verheul

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

These data indicate that using PARPis is a promising treatment strategy for patients with non-BRCA-associated histologies harboring biallelic BRCA LoF. WGS allows to accurately detect complete LoF of BRCA and homologous repair deficiency (HRD) signature as well as oncogenic drivers that may contribute to resistance, using a single assay.

Keyphrases

breast cancer risk
dna damage
high throughput
machine learning
electronic health record
transcription factor
replacement therapy
artificial intelligence
big data
single cell
data analysis